Results of NCI-sponsored phase I trials with XXXX .

@entity1 @entity644 @entity137 @entity390 @entity417 @entity882 @entity2167 @entity5 @entity3003 @entity1272 @entity900 @entity391 @entity0 @entity75 @entity421 @entity581 @entity1011 @entity4841 @entity925 @entity1210
@entity3003 has been developed for clinical trials as a less nephrotoxic, less emetogenic analog of @entity900 . In preclinical @entity5 models it was less potent than the parent compound on a molar basis, but reduced @entity137 allowed comparable antitumor doses to be given. In phase I studies its dose-limiting @entity137 were reversible myelosuppression, especially @entity882 . @entity1210 and @entity417 occurred to a lesser degree. Other reported @entity137 included @entity390 , @entity391 , malaise, @entity925 , @entity4841 , @entity2167 , @entity1272 , and @entity644 . @entity390 and @entity391 occurred frequently, but was much less severe than that observed with @entity900 . The incidence of serum @entity1011 elevations was low. The increase was usually reversible and occurred only in association with administration of @entity581 , or abnormal pretreatment renal function. Recommended phase II doses by schedule are: bolus every 4 weeks, 400-500 mg/m2 (560 mg/m2 in @entity1 ); 24 hour continuous infusion every 4 weeks, 320-400 mg/m2; weekly bolus for 4 consecutive weeks with 2 weeks rest, 100-125 mg/m2 (175 mg/m2 in @entity1 ); bolus for 5 consecutive days every 4 weeks, 77-95 mg/m2. Objective responses were observed during these phase I studies in adult @entity1 ( @entity0 ) and @entity1 ( @entity421 , @entity75 ). In addition to phase II evaluations in all major @entity5 types, plans for phase III studies in selected @entity5 are underway.
